demonstrated that serum levels of CTRP2 in CAD patients were independently associated with the progression of CAD, which indicates that CTRP2 might be considered as a novel biomarker for assessing the risk of CAD (34). The gene discussed is C1QTNF2; the disease is coronary artery disorder.